White paper
High potency drugs – from molecule to market
June 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing PCI
To print or download a PDF version of this article, click here.
Tau pathology as the key to understanding Alzheimer’s disease
June 5, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Alzheimer’s disease (AD) is a neurodegenerative disorder and the most common type of dementia (60–70%)[1], causing problems with memory, language, …
Clinical Trial Success: How Relationships Are Key
June 2, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing contract research organisations, cros
Jeffrey Zucker, Vice President of Feasibility and Recruitment Optimisation at Worldwide Clinical Trials, offers strategies for establishing and maintaining key …
Europe vs USA: New drug approvals
June 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NDA, regulatory affairs
Dr Terese Johansson, Regulatory Affairs Consultant NDA Group AB, examines the drop in US approvals while observing no similar trend …
Crunch Time: The Impact of Serialisation Requirements on Packaging Operations
March 31, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing PCI services
Introduction More than three years have passed since the US federal government signed the Drug Supply Chain Security Act (DSCSA) …
Cmed release Global Strategic and Regulatory Consulting Booklet
March 14, 2012Research and Development
The regulatory environments within the industry continue to change and vary internationally. Cmed’s regulatory and medical professionals keep track of …
Introducing SHL’s first White Paper: “Auto Injectors: From Planning to Launch”
January 3, 2012Manufacturing and Production auto injector, autoinjector, autoinjector manufacturing, autoinjector white paper, shl white paper
SHL is officially introducing the company’s first White Paper on the topic of “Auto Injectors; From Planning to Launch” with …
Adaptive Trial Design
November 24, 2011Research and Development
Despite the burgeoning interest in Adaptive Trial Design (ATD), an extremely powerful tool when used effectively in the appropriate circumstances, …
The Project Management Office – Accelerating Project Management Maturity
February 3, 2011Sales and Marketing Kinapse, White paper
Success in the life sciences industry depends on allocation of scarce resource to the right projects at different stages of …
Offshore outsourcing in Regulatory Affairs and Pharmacovigilance
November 22, 2010Sales and Marketing Kinapse, White paper
Based on Kinapse’s direct experience, we explore the emerging environment for regulatory and pharmacovigilance offshore outsourcing within the biopharmaceutical industry …
New Commercial Realities
November 4, 2010Sales and Marketing Kinapse, White paper
Faced with a changing healthcare environment and the prospect of diminishing commercial returns, pharmaceutical companies must undertake a fundamental and …
Sowing into Good Ground: Using “personalized medicine” for optimal treatment value
October 26, 2010Sales and Marketing Kinapse, White paper
As demonstrating value for the “average patient” becomes ever more difficult, Health Economics and Outcomes Research leaders can use “personalised …
In with the ‘new’: A leaner, fitter biosciences sector – 2010
October 18, 2010Sales and Marketing Kinapse, White paper
The biosciences sector has witnessed numerous challenges during recent years, as the global economic downturn has adversely impacted sector liquidity …
Discovery Innovation – Productive Partnering For Shared Success
October 15, 2010Sales and Marketing Kinapse, White paper
Partnering is an integral feature within today’s pharmaceutical industry. While the conventional wisdom suggests that Phase II represents the optimum …
New Commercial Realities – Part 4 Key implications of this changing industry landscape for pharmaceutical commercial operations – governance
October 5, 2010Sales and Marketing Kinapse, White paper
Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
